Active, Not Recruiting
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NCT05984602
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +8 more
- Locations
-
- Ambulatory Care Center New York, United States
- Clinical Cancer Center New York, United States
- NYU Langone Ambulatory Care Center East 38th Street New York, United States